In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its ...
As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. France’s public health agency, the Haute ...
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 ...
An announcement from Valneva ( (VALN)) is now available. Valneva SE announced positive final results from its Phase 2 clinical trial for the chikungunya vaccine IXCHIQ® in children aged one to eleven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results